– USA, CA – BioVentrix, Inc., a privately-held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration, today announced the appointment of Raymond Cohen as the Board chairman alongside Rinda Sama and Andrew Hinson joining the board of directors.
“This is an important time in the Company’s history. BioVentrix has an accomplished and experienced CEO in Jim Dillon who now has several industry experts to provide support and guidance as the Company seeks to complete its PMA study, gain FDA approval and execute a successful IPO,” said Board chairman, Raymond Cohen.
The additions of Mrs. Sama and Hinson brings the total of independent medical device industry experts on the BioVentrix board to six, including CEO Jim Dillon and current board members, Steve Healy and George Fazio.
Jim Dillon, CEO of BioVentrix, commented, “The Revivent TC system, which has achieved Breakthrough Designation by the U.S. FDA, is designed to treat congestive heart failure patients with an enlarged left ventricle for which, until now, there has been no treatment. Clinical results continue to be impressive and reimbursement is already in place. We believe the combination of these factors will allow for highly successful commercialization and rapid adoption in the United States.”
About Raymond Cohen
Mr. Cohen has over 40 years of experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen, an accredited public company director, currently serves as the CEO and member of the board of directors of Axonics, Inc. (Nasdaq: AXNX).
About Andrew Hinson
Andrew Hinson currently serves as a member of the board of directors at BioLife Solutions, Inc. (Nasdaq: BLFS). Mr. Hinson has over 30 years of experience in pharmaceutical, biotechnology, and medical device development that includes specific expertise in congestive heart failure, clinical research and development, regulatory affairs, and business development.
Andrew Hinson holds a B.S. in Biological Sciences from the University of Cincinnati.
About Rinda Sama
Rinda Sama currently serves as COO of Axonics, Inc. Mr. Sama has over 20 years of experience in medical devices and is an expert in manufacturing and operations, as well as worldwide regulatory affairs.
Rinda Sama holds an M.S. in Biomedical Engineering from the University of Southern California and an MBA from the University of California, Irvine.
BioVentrix, Inc., is a privately held medical device company headquartered in San Ramon, California. The Company’s mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy. BioVentrix’s Revivent TC system received the CE Mark and is currently pending FDA approval in the United States.
For more information: https://bioventrix.com/en-us/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.